Novartis completes acquisition of Regulus Therapeutics

Novartis acquires Regulus for $7.00 per share in cash, with potential to receive an additional $7.00 per share in cash

https://www.novartis.com/news/media-releases/novartis-completes-acquisition-regulus-therapeutics

https://www.sec.gov/Archives/edgar/data/1505512/000119312525105845/d873263dex21.htm

Please read the SEC documents regarding this current security and understand that I do own of these shares. This isn’t an offer or solicitation to buy shares.

Under the terms of the transaction, which has been unanimously approved by the Boards of Directors of both companies, Novartis will, through an indirect wholly owned subsidiary, commence a tender offer to purchase all outstanding shares of Regulus common stock. Holders of Regulus common stock would receive USD 7 per share in cash at closing and a contingent value right (“CVR”) with a value of up to USD 7 per share payable in cash upon the achievement of a regulatory milestone.

The stock closed at $8.16….

All expressions of opinion reflect the judgment of the author and are subject to change. The information should not be construed as a recommendation. The foregoing content is subject to change at any time without notice content provided herein is for informational purposes only there is no guarantee these statements or forecasts will prove correct. past performance is no guarantee of future results. Investing involves risk including the possible loss of capital.